T-Rapa CAR-T Cells via Rapamycin Conditioning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chimeric antigen receptor (CAR) therapies face challenges in overall safety and efficacy, particularly in treating solid tumors, and the lymphodepleting preconditioning regimen used to enhance CAR T-cell persistence and survival can cause damage to healthy cells and have a negative impact on patient quality of life, with reported life-threatening toxicities.
Innovation Solution
The development of T-Rapa cells, which are generated by conditioning CD3+ T-cells with rapamycin and transducing them with a vector expressing a CAR, allowing for reduced preconditioning intensity and enhanced anti-tumor effects against a broad spectrum of tumor types, potentially lowering toxicities and improving treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lymphodepleting preconditioning regimen is used to increase CAR T-cell survival and persistence, then clinical response is improved, but damage to healthy cells occurs and patient quality of life deteriorates
Solution Approach 1:
The patent changes the pharmacological parameter by using rapamycin (an mTOR inhibitor) instead of traditional lymphodepleting chemotherapy agents. This parameter change achieves CAR T-cell persistence and survival enhancement while avoiding the harmful effects of lymphodepletion on healthy cells, thus resolving the contradiction between improving reliability and reducing harmful factors
Solution Approach 2:
Rapamycin acts as an intermediary substance that mediates between the need for CAR T-cell persistence and the avoidance of healthy cell damage. It provides the necessary immunomodulatory effects to enhance T-cell survival without the toxic side effects of conventional lymphodepleting regimens, thereby resolving the technical contradiction
2Reliability
If lymphodepleting preconditioning regimen is used to enhance CAR T-cell persistence, then clinical response is improved, but life-threatening toxicities occur
Solution Approach 1:
The patent changes the treatment parameter from lymphodepleting chemotherapy to rapamycin-based immunomodulation. This parameter change maintains CAR T-cell persistence and clinical response while eliminating the life-threatening toxicities associated with conventional preconditioning regimens, thus resolving the contradiction between reliability improvement and harmful factor reduction
3Adaptability or versatility
If conventional CAR therapy is used for solid tumors, then treatment approach is established, but efficacy is insufficient
Solution Approach 1:
The patent changes the immunomodulatory parameter by using rapamycin to enhance CAR T-cell functionality. This parameter change improves efficacy against solid tumors while maintaining the established CAR therapy approach, thereby resolving the contradiction between adaptability and reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
T-Rapa cells demonstrate potent effector functions and long-term persistence with reduced production of pro-inflammatory cytokines, such as IFN-γ, potentially reducing the risk and severity of cytokine release syndrome and improving the safety and efficacy of CAR therapy.
Implementation Method 1
conditioning ex vivo CD3+ T-cells with rapamycin to generate T-Rapa cells
Implementation Method 2
transducing the T-Rapa cells in vitro with a vector that expresses the CAR
Data Source
AI summary
The present disclosure provides chimeric antigen receptor (CAR)-T-Rapa cells and methods of making and using them. Specifically, methods of producing T-Rapa cells that can express chimeric antigen receptors is provided.